Depacon / Depakene / Depakote

In recent years, dozens of studies have been published illustrating an increased risk for birth defects linked to antiepileptic drugs containing sodium valproate such as Depacon, Depakene, and Depakote.  While these drugs are effective in the mitigation of seizures, the risks posed to developing babies cannot go overlooked.  Here, I will summarize one such

In January of last year, a team of researchers led by E. Campbell published an article in Epilepsia titled “Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero.”, marking yet another piece of professional research illustrating the risks of prenatal exposure to drugs containing sodium valproate such as Depacon,

In July, 2011, Lancet Neurology published an article titled “Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.” that was written by a team from Stockholm led by T. Tomson.  This study is yet another example of peer-reviewed research demonstrating that serious risks are

Titled “Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.”, an article by J. Morrow and a team from Belfast (UK) published in the February, 2006 edition of Journal of Neurology, Neurosurgery, and Psychiatry aimed to “assess the relative risk of major congenital malformation (MCM)

In July, 2014, a team of Norwegian researchers led by K.O. Nakken published an article in Tidsskr Nor Laegeforen titled “Antiepileptic drugs and congenital malformations”, evaluating the consequences of prenatal exposure to epilepsy drugs containing sodium valproate, such as Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.).  To-date, dozens of

From Stockholm, Sweden, a 2008 piece titled “Teratogenic effects of antiepileptic drugs.” and appearing in the medical journal, Seizure, by T. Tomson et al. yet again demonstrates the postnatal risks of prenatal exposure to epilepsy drugs containing sodium valproate such as Depakote, Depakene, and Depacon (Abbott Laboratories, Inc.).

Here, it is stated